Perceptive Advisors Llc, La Jolla Pharmaceutical Company (LJPC)’s insider Obtained 50,000 Shares; 3 Analysts Are Bullish Zoe's Kitchen, Inc. (ZOES) Last Week

February 20, 2018 - By Darrin Black

Perceptive Advisors Llc is an insider of La Jolla Pharmaceutical Co. That well-know insider recently paid for 50,000 shares in the Pinksheet-listed company with the deal value totalling $1.62 million US Dollars. The number is according to the filing revealed price of $32.4 for a share. This acquisition decreased his ownership of the company to 16.32% total market capitalization or 3.61 million shares.

Among 9 analysts covering Zoe’s Kitchen (NYSE:ZOES), 3 have Buy rating, 1 Sell and 5 Hold. Therefore 33% are positive. Zoe’s Kitchen had 40 analyst reports since August 6, 2015 according to SRatingsIntel. Robert W. Baird downgraded Zoe's Kitchen, Inc. (NYSE:ZOES) on Monday, May 22 to “Neutral” rating. Cowen & Co maintained it with “Hold” rating and $14.0 target in Friday, August 18 report. The stock of Zoe's Kitchen, Inc. (NYSE:ZOES) earned “Underperform” rating by Credit Suisse on Friday, August 18. Robert W. Baird maintained it with “Outperform” rating and $40 target in Tuesday, August 23 report. On Wednesday, September 27 the stock rating was maintained by Jefferies with “Hold”. Maxim Group maintained the stock with “Buy” rating in Monday, August 14 report. The stock of Zoe's Kitchen, Inc. (NYSE:ZOES) has “Outperform” rating given on Thursday, August 17 by Telsey Advisory Group. Jefferies maintained the shares of ZOES in report on Friday, December 22 with “Buy” rating. The firm has “Buy” rating given on Friday, November 20 by Maxim Group. The stock has “Hold” rating by Robert W. Baird on Monday, September 18. See Zoe's Kitchen, Inc. (NYSE:ZOES) latest ratings:

02/01/2018 Broker: Robert W. Baird Rating: Hold New Target: $15.0 Maintain
22/12/2017 Broker: Jefferies Rating: Buy New Target: $20.0 Maintain
09/11/2017 Broker: Cowen & Co Rating: Hold New Target: $12.0 Maintain
10/11/2017 Broker: Robert W. Baird Rating: Neutral Old Target: $13 New Target: $13 Maintain
10/11/2017 Broker: Jefferies Old Rating: Hold New Rating: Buy Upgrade
02/11/2017 Broker: Maxim Group Rating: Buy New Target: $20.0 Maintain
27/09/2017 Broker: Jefferies Rating: Hold New Target: $16.0 Maintain
18/09/2017 Broker: Robert W. Baird Rating: Hold New Target: $15.0 Maintain

Zoe's Kitchen, Inc., through its subsidiaries, develops and operates a chain of fast-casual restaurants. The company has market cap of $268.10 million. It operates a range of restaurant formats, including in-line, end-cap, and free-standing restaurants. It has a 1371 P/E ratio. As of May 25, 2017, the firm operated 219 owned and franchised restaurants in 20 states of the United States.

The stock decreased 1.37% or $0.19 during the last trading session, reaching $13.71. About 524,459 shares traded or 32.46% up from the average. Zoe's Kitchen, Inc. (NYSE:ZOES) has declined 49.51% since February 20, 2017 and is downtrending. It has underperformed by 66.21% the S&P500.

Investors sentiment decreased to 0.98 in 2017 Q3. Its down 0.35, from 1.33 in 2017Q2. It dropped, as 20 investors sold Zoe's Kitchen, Inc. shares while 22 reduced holdings. 16 funds opened positions while 25 raised stakes. 18.57 million shares or 15.63% less from 22.02 million shares in 2017Q2 were reported. Jennison Associates Ltd Limited Liability Company holds 0.02% or 1.36 million shares. Highlander Capital Mgmt Llc invested in 0.14% or 14,500 shares. Virtu Financial Ltd Liability Com invested in 18,785 shares. Swiss Fincl Bank holds 0% or 29,800 shares in its portfolio. Bank Of New York Mellon Corporation holds 580,015 shares or 0% of its portfolio. Ubs Asset Americas holds 0% or 12,000 shares. Northern Trust Corp invested in 0% or 228,324 shares. Engineers Gate Manager Lp reported 0.06% stake. Hhr Asset Mngmt holds 614,878 shares. Ellington Group Limited Company invested 0.07% in Zoe's Kitchen, Inc. (NYSE:ZOES). Alliancebernstein Ltd Partnership accumulated 0% or 11,600 shares. Jpmorgan Chase reported 0.01% stake. Legal General Gp Pcl accumulated 0% or 5,863 shares. Blue Bell Private Wealth Ltd Llc accumulated 0% or 375 shares. Geode Limited Liability accumulated 150,417 shares.

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company has market cap of $734.56 million. It engages in developing LJPC-501, a formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension; and LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. It currently has negative earnings. The firm is also developing LJPC-30S, which is the gentamicin derivative program for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

The stock decreased 2.07% or $0.7 during the last trading session, reaching $33.17. About 301,834 shares traded. La Jolla Pharmaceutical Company (NASDAQ:LJPC) has risen 128.65% since February 20, 2017 and is uptrending. It has outperformed by 111.95% the S&P500.

Investors sentiment decreased to 1.61 in 2017 Q3. Its down 0.20, from 1.81 in 2017Q2. It fall, as 10 investors sold La Jolla Pharmaceutical Company shares while 21 reduced holdings. 25 funds opened positions while 25 raised stakes. 23.31 million shares or 1.99% less from 23.78 million shares in 2017Q2 were reported. Voya Inv Management Ltd Liability Corp holds 8,172 shares. Blackrock reported 1.16 million shares stake. Jane Street Gru Limited Liability has invested 0% in La Jolla Pharmaceutical Company (NASDAQ:LJPC). American Intll Gp Inc reported 11,721 shares. Wolverine Asset Management Ltd Limited Liability Company holds 0.01% or 32,338 shares in its portfolio. Prudential Incorporated holds 0.01% or 179,760 shares. 83,744 were accumulated by Bancorporation Of New York Mellon. Hollencrest Llc stated it has 22,092 shares or 0.11% of all its holdings. Geode Capital holds 0% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 149,579 shares. Royal Fincl Bank Of Canada invested in 2,453 shares or 0% of the stock. Price T Rowe Md reported 307,879 shares. Sphera Funds Management Limited holds 0.74% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 150,000 shares. Tiaa Cref Inv Mgmt Ltd has 46,063 shares. Jennison Ltd Liability Co invested in 0.07% or 2.05 million shares. Goldman Sachs Group Incorporated invested 0% in La Jolla Pharmaceutical Company (NASDAQ:LJPC).

Since December 29, 2017, it had 1 buy, and 1 sale for $5.40 million activity. 10,000 La Jolla Pharmaceutical Company (NASDAQ:LJPC) shares with value of $323,208 were sold by Douglass Laura L.. On Tuesday, February 13 PERCEPTIVE ADVISORS LLC bought $5.73M worth of La Jolla Pharmaceutical Company (NASDAQ:LJPC) or 175,000 shares.

Analysts await La Jolla Pharmaceutical Company (NASDAQ:LJPC) to report earnings on February, 22. They expect $-1.26 earnings per share, up 12.50% or $0.18 from last year’s $-1.44 per share. After $-1.19 actual earnings per share reported by La Jolla Pharmaceutical Company for the previous quarter, Wall Street now forecasts 5.88% negative EPS growth.

Among 8 analysts covering La Jolla Pharmaceutical Company (NASDAQ:LJPC), 5 have Buy rating, 3 Sell and 0 Hold. Therefore 63% are positive. La Jolla Pharmaceutical Company has $90.0 highest and $20.0 lowest target. $46.86’s average target is 41.27% above currents $33.17 stock price. La Jolla Pharmaceutical Company had 18 analyst reports since August 11, 2015 according to SRatingsIntel. Cowen & Co initiated the shares of LJPC in report on Tuesday, February 9 with “Outperform” rating. The rating was downgraded by J.P. Morgan on Friday, December 8 to “Sell”. The company was initiated on Wednesday, August 30 by J.P. Morgan. The firm has “Buy” rating by Chardan Capital Markets given on Tuesday, September 8. On Tuesday, January 30 the stock rating was maintained by H.C. Wainwright with “Buy”. On Friday, December 8 the stock rating was downgraded by JP Morgan to “Underweight”. As per Friday, December 22, the company rating was maintained by Cowen & Co. Jefferies maintained the shares of LJPC in report on Monday, June 12 with “Buy” rating. As per Thursday, August 31, the company rating was maintained by Jefferies. The company was downgraded on Tuesday, August 11 by Zacks.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>